BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSDBy Nasdaq OMXMay 22, 2017, 8:07 PM UTC
BusinessTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSDBy Nasdaq OMXMay 22, 2017, 8:07 PM UTC
